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Synthesis and activity of a novel inhibitor of
nonsense-mediated mRNA decay†
Victoria J. B. Gotham,a,b Melanie C. Hobbs,a Ryan Burgin,a David Turton,b
Carl Smythe*b and Iain Coldham*a
During eﬀorts to prepare the known compound NMDI1, a new
tetracyclic compound, called VG1, was prepared in six steps. This
compound was found to have good activity as an inhibitor of non-
sense-mediated mRNA decay.
A significant proportion of genetic diseases, as well as many
cancers, are associated with a particular type of mutation
which gives rise to a premature termination codon (PTC)
before the genuine stop codon.1 PTC-associated diseases
include cases of Duchenne muscular dystrophy, cystic fibrosis,
β-thalassaemia, retinitis pigmentosa, von Willebrand disease,
Robinow syndrome, haemophilia, spinal muscular atrophy
and Rett syndrome. mRNAs containing PTCs are detected and
degraded by a process known as nonsense-mediated mRNA
decay (NMD),2–4 which reduces the expression of the corres-
ponding gene to a low level. It is the subsequent lack of
protein that causes the symptoms of PTC-associated diseases.
The PTCs that trigger NMD can occur due to single base pair
mutations, reading frame shifts due to deletions or insertions,
or mutations in splice sites or splicing regulatory sequences
that give rise to aberrant splicing.2–4 At the mRNA level, PTCs
can arise from errors in transcription, transcription initiation
upstream of the correct site coupled with the location of a
termination codon in the region before the proper start
site, alternative splicing, or programmed frameshifts during
translation.2–4
One potential approach to the treatment of diseases caused
by PTC mutations is the inhibition of NMD. Therefore there is
a need to discover and develop drugs that inhibit NMD selec-
tively. In addition, NMD inhibitors can be useful tools for
studying the NMD mechanism and related pathways that
utilise some of the same factors. In 2007, Lejeune and co-
workers5 found that a tetracyclic compound called NMDI1
(Fig. 1) was able to inhibit both nucleus-associated and cyto-
plasmic NMD. The compound appears to be a specific inhi-
bitor of NMD: it does not aﬀect the splicing of pre-mRNA
reporter transcripts, the amount of pre-mRNA, translation
eﬃciency or the miRNA decay pathway.5 It is non-cytotoxic,
even at high concentrations, and does not induce the for-
mation of stress granules.5
The synthesis of NMDI1 was reported by Bisagni and co-
workers.6,7 The overall yield was poor (0.5% over 11 steps) and
we had diﬃculties on attempted repetition of the published
procedure (see ESI†). Keeling and co-workers have recently
reported a synthesis of NMDI1 by a modified route (total 13
steps) in which the final 7 steps were identical to those used
by Bisagni and co-workers; however, they report no experi-
mental details.8
There is clearly a need for a NMD inhibitor whose synthesis
is more eﬃcient and reproducible. We have synthesised in
only 6 steps a close structural analogue of NMDI1, called VG1,
by using a diﬀerent route from that described above.6–8 We
found that VG1 inhibits NMD equally well as NMDI1 and is
therefore a suitable candidate for use as a tool to investigate
NMD and related mechanisms, and possibly for development
as a drug for diseases caused by PTC mutations.
VG1 was synthesised from commercially available 2,3-di-
bromopyridine and 2,5-dimethylaniline (Scheme 1). These were
heated at 140 °C for 16 h to give bromide 1 in 76% yield. An
aldehyde was then installed para to the amino group. The use
of POCl3 and DMF (Vilsmeier reaction)
9,10 failed to give the
desired aldehyde, but the use of AlCl3 and MeOCHCl2 (Rieche
formylation)11,12 was successful and gave aldehyde 2. This
Fig. 1 Structure of NMD inhibitor NMDI1.
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compound was not purified but was treated directly with
NaClO2 and NH2SO3H as a chlorine scavenger,
13–15 to give the
carboxylic acid 3 in 66% yield from bromide 1. The acid was
converted to amide 4 in 94% yield by using the commercially
available aminoacetaldehyde diethylacetal and the coupling
reagent COMU.16 Deprotection of the acetal with polyphospho-
ric acid was followed by in situ cyclisation and dehydration17 to
give compound 5 in 70% yield. An intramolecular palladium-
catalysed cross-coupling reaction18 was used to convert
bromide 5 into tetracycle VG1 in 54% yield.
Attempted conversion of the lactam 5 to the chloropyridine
was unsuccessful by using POCl3, PhP(O)Cl2, PCl3, or PCl5 in
POCl3. Chlorination of VG1 was also attempted but the only
isolable products obtained, after treatment of either com-
pound 5 or VG1 with PCl5 in POCl3, were N-chloro derivatives
(see ESI†). Chlorination on the nitrogen atom of an amide has
literature precedent.19–21 Unfortunately, this meant that we
were not able to prepare NMDI1 using this synthesis. However,
we had prepared a close analogue in VG1 and decided to test
the activity of this compound.
To test the ability of VG1 to inhibit NMD we utilised a well-
established assay for the measurement of NMD within cells.22
HeLa cells were transfected with either one of two reporter
plasmids, pmCMV-Gl (NORM) or pmCMV-Gl (TER),22–24
referred to as NORM and TER. The NORM plasmid contains a
hybrid human/mouse β-globin gene. This was constructed by
Maquat and Kinniburgh23 by substituting sequences in the
human β-globin gene extending from the BamH1 site in exon
II with analogous sequences from the mouse β-globin gene.
The resulting hybrid gene contains exon I, intron I and most
of exon II of the human β-globin gene, and 18 base pairs of
exon II, intron II and exon III of the mouse β-globin gene. The
TER plasmid contains the same chimaeric gene but with a
PTC mutation (CAG to TAG) in codon 39, located in exon II.
The cloning of NORM and TER sequences into the mRNA pro-
ducing plasmid pCMV, and the characterisation of resultant
mRNA has been previously described.22 TER and NORM tran-
scripts are subject to splicing, and TER, but not NORM, spliced
mRNA is subject to NMD.22 Fig. 2 shows a plasmid map and
the structure of the hybrid genes. In order to control for trans-
fection eﬃciency, cells were also transfected with the reference
plasmid phCMV-MUP (referred to as MUP), which encodes
mouse major urinary protein.25 After 24 h, the transfection
medium was removed from cells and replaced with culture
medium containing either DMSO or NMDI1 or VG1 at a final
concentration of 5 μM made up from a 5 mM stock solution in
DMSO. Each compound was added both to cells transfected
with NORM and cells transfected with TER. After 20 h, total
RNA was extracted and reverse transcribed. The amount of
NORM, TER and MUP cDNA was determined by qPCR, where
the amount of cDNA serves as a proxy measurement for mRNA
as has been described previously.27,28 To ensure that the qPCR
reaction products reflected the appropriately spliced mature
mRNA, the cDNA generated from RNA extracted from both
NORM and TER transfected cells was amplified by standard
PCR using identical primers and DNA products which corre-
spond to their cognate mRNAs were analysed for size by
agarose gel electrophoresis. These showed that PCR products
correspond to correctly spliced mRNA (Fig. S2 in ESI†).
The inferred amounts of NORM and TER mRNA, each
expressed as a ratio of the respective inferred amount of MUP
mRNA in each sample, were compared in order to determine
the NMD eﬃciency. As expected, for cells treated with DMSO
only, the amount of TER mRNA was significantly lower than
the amount of NORM mRNA (0.22 times the amount of NORM
mRNA), indicating that TER mRNA was eﬃciently degraded by
NMD (Fig. 3A, first and second bars from left). When cells
were treated with VG1, the amount of TER mRNA increased to
Scheme 1 Synthesis of VG1.
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0.70 times the amount of NORM mRNA, showing that NMD
was inhibited (Fig. 3A, fifth and sixth bars from left). VG1
inhibited NMD to the same extent as NMDI1 (Fig. 3A, third
and fourth bars from left).
The eﬀect of the dose of VG1 on NMD inhibition was then
investigated. Cells were transfected with the NMD reporter
plasmids, as described above. After 24 h, the transfection
medium was removed from cells and replaced with culture
medium containing either DMSO or VG1 at a final concen-
tration of 0.2, 1, 5, 25 or 125 μM made up from a stock solu-
tion in DMSO. After 20 h, total RNA was extracted and reverse
transcribed. The amount of NORM, TER and MUP cDNA was
determined by qPCR and the inferred amounts of NORM and
TER mRNA, each expressed as a ratio of the respective inferred
amount of MUP mRNA in each sample, were compared in
order to determine the NMD eﬃciency. To ensure that the
PCR primers used generated a reaction product corresponding
to spliced RNA and not unspliced pre-mRNA, the amplified
PCR products from RNA extracted from cells transfected with
either NORM, or TER, were examined by DNA agarose gel elec-
trophoresis (Fig. S2†). In each case, these showed the presence
of a DNA fragment of 150 bp corresponding to correctly
spliced mRNA. In qPCR analyses, the amount of TER mRNA
relative to NORM mRNA, and therefore NMD inhibition,
increased as VG1 concentration increased, reaching a
maximum at 25 μM, at which concentration the amount of
TER mRNA was 0.94 times the amount of NORM mRNA
(Fig. 3B). There was no further NMD inhibition at 125 μM.
Thus high levels of inhibition of NMD were achieved by treat-
ing cells with 5–25 μM VG1, assuming that if NMD were fully
Fig. 2 pmCMV-Gl (NORM) and pmCMV-Gl (TER) plasmids. (A) Plasmid map. The plasmids contain a mouse cytomegalovirus (mCMV) promoter, a
hybrid human/mouse β-globin gene and a gene for ampicillin resistance. The map was created using the PlasMapper program.26 (B) Structure of the
hybrid human/mouse β-globin gene. Grey boxes are introns. Start (ATG) and stop (TAA) codons are shown. The BamH1 site marks the boundary
between sequences from the human and mouse genes. The TER plasmid is identical to NORM, except that a PTC mutation (CAG to TAG), has been
introduced in codon 39 located in exon II.
Fig. 3 NMD inhibition by VG1. (A) Cells transfected with the NMD reporter constructs were treated with either DMSO or 5 μM NMDI1 or VG1 for
20 h. The amount of reporter β-globin mRNA (NORM or TER) is controlled to the amount of MUP mRNA. The data are normalised to the amount of
NORM mRNA (controlled to the amount of MUP mRNA) for DMSO-treated cells. Error bars show the standard error in the mean obtained from three
independent experiments. (B) Cells transfected with the NMD reporter constructs were treated with VG1 at the concentrations indicated for 20 h.
The amount of TER β-globin mRNA is expressed relative to the amount of NORM β-globin mRNA (both controlled to the amount of MUP mRNA) for
each concentration. Error bars show the standard error in the mean obtained from three independent experiments for 0.2, 1 and 5 μM VG1 and from
two independent experiments for 25 and 125 μM VG1.
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inhibited, the amount of TER mRNA would be equal to the
amount of NORM mRNA.
NMDI1 has been reported to have little eﬀect on cell viabi-
lity.5 When cells were seeded as normal (104 cells per cm2) and
treated with 5 μM VG1 for 24 h, the rate of proliferation
appeared similar to cells treated with DMSO alone (Fig. S1A
in ESI†) and there was little evidence of increased pyknosis or
karyorrhexis (indicators of necrosis or late-stage apoptosis)
suggesting that, as with NMDI1, eﬀective doses on this
timescale are not toxic for cell survival. The eﬀect of VG1 dose
on cells after 20 h exposure was also investigated (Fig. S1B†).
As before, at concentrations up to 5 μM, there was no
obvious eﬀect on cell number or morphology. When VG1
was added to cell media at 25 μM and cells were incubated
with compound for 20 h, there was some indication of altered
cell morphology in a minority of cells, suggestive of some tox-
icity at higher concentrations and possible induction of apop-
tosis (Fig. S1B†). Further analyses of the eﬀects of longer
exposure at 25 μM or the use of higher concentrations were
not possible due to insolubility of VG1 in cell media at high
concentrations. Exploration of the induction of apoptosis at an
intermediate concentration of VG1 (10 μM, Fig. S1C†) was eval-
uated by immunoblotting total cell lysates for the appearance
of the cell marker of apoptotic induction, activated (cleaved)
Caspase 3.29 These data (Fig. S1C†) indicated that, at this con-
centration and time scale, there was no evidence of elevated
levels of apoptotic cell death under these conditions. Taken
together our data suggest that, as with NMDI1, eﬀective doses
of VG1 over a 24 h time scale are not toxic for cell survival.
Inhibiting NMD is a promising approach towards treating
diseases caused by PTC mutations as, in many cases, the trun-
cated protein that would result if the PTC-containing mRNA
were to be translated could be at least partially functional and
could relieve some of the symptoms of the disease. Obviously,
the function of the truncated protein would depend on the
location of the PTC within the mRNA. As an example of the
potential of this approach, when cultured fibroblasts from a
patient with Ullrich’s disease (which is caused by a PTC in the
gene for the extracellular matrix protein collagen VI α2) were
treated with inhibitors of the NMD factor SMG1, there was an
increase in the expression of truncated collagen VI α2 which
partially restored the function of the extracellular matrix.30
However, SMG1 inhibitors are unlikely to be able to be used
clinically as they are toxic and are not specific for SMG1. Other
small molecules that have been used to inhibit NMD have not
yet reached clinical trials of NMD inhibition.31–36
One approach for treating PTC-associated diseases involves
the use of a class of compounds called ribosome readthrough
promoters.37,38 These compounds induce the ribosome to
“read through” a PTC, allowing a full-length protein to be pro-
duced from the transcript. However, the eﬃcacy of read-
through promoters is limited by a paucity of PTC-containing
mRNAs available for readthrough, as most are degraded
rapidly by NMD. Inhibiting NMD, in combination with read-
through therapy, should mean that fewer PTC-containing
mRNAs are degraded and therefore more are available for read-
through. This approach has been used by Lejeune and co-
workers,33 who found that the eﬀect of 5 μM NMD inhibitor
amlexanox combined with 25 μM readthrough promoter
PTC124 was greater than that of either drug on its own in
increasing iodide eﬄux in 6CFSMEo cystic fibrosis cells.
Keeling and co-workers have shown that NMDI1 was able to
enhance the therapeutic eﬀect of at least a subset of read-
through promoters called aminoglycosides in IduaW392X mice
(which have a premature stop codon in the gene encoding α-L-
iduronidase).8
In this paper, we have developed a synthesis of an analogue
of NMDI1 and have found that our compound, VG1, inhibited
NMD to the same extent as NMDI1. Our synthesis requires
only 6 steps and proceeds in 18% overall yield. Lejeune and
co-workers presented evidence that NMDI1 inhibits the inter-
action between two key NMD factors, UPF1 and SMG5.5 UPF1
forms part of a complex that recognises the PTC-containing
mRNA after the first round of translation terminates at the
PTC. The protein undergoes cycles of phosphorylation and de-
phosphorylation, which allow it to take part in multiple
rounds of NMD. SMG5 is one of the proteins that mediates the
de-phosphorylation of UPF1, and inhibition of the UPF1-SMG5
interaction may cause UPF1 to become trapped in a hyper-
phosphorylated state. Given the similarity between the struc-
tures of VG1 and NMDI1, it is likely that the compounds
inhibit NMD by the same mechanism, and therefore, that VG1
also inhibits the interaction between UPF1 and SMG5,
although this still needs to be confirmed. It is conceivable that
NMDI1 is converted into VG1 in the cell and that the active
form of the compounds is the same. The compound VG1
passed the filter on an online PAINS (pan assay interference
compounds) false positive remover tool,39 which helps to vali-
date VG1 as a genuine NMD inhibitor. Work is required to
establish the mechanism of action of VG1. Whatever the
outcome, VG1 will be a useful tool for developing an under-
standing of both the mechanism of NMD and of other related
mRNA decay pathways.
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